Mikhal E. Cohen

Dr. Mikhal E. Cohen

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2010 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
ILIris Lavon
Iris Lavon
DZDaniel Zrihan
Daniel Zrihan
AGAvital Granit
Avital Granit
OEOfira Einstein
Ofira Einstein
NFNina Fainstein
Nina Fainstein
TSTali Siegal
Tali Siegal
Gliomas express many genes that play a role in neural precursor cells (NPCs), but no direct comparison between glioma and stem cell (SC) gene expression profiles has been performed. To investigate the similarities and differences between gliomas and SCs, we compared the microRNA (miRNA) expression signatures of glial tumors, embryonic SCs (ESCs), NPCs, and normal adult brains from both human and mouse tissues. We demonstrated that both human gliomas (regardless of their grade) and methylcholanthrene-induced mouse glioma shared an miRNA expression profile that is reminiscent of NPCs. About half of the miRNAs expressed in the shared profile clustered in seven genomic regions susceptible to genetic/epigenetic alterations in various cancers. These clusters comprised the miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373, which are upregulated in gliomas, ESCs, and NPCs. The bipartite cluster of 7 + 46 miRNAs on chromosome 14q32.31, which might represent the largest tumor suppressor miRNA cluster, was downregulated in the shared expression profile. This study provides the first evidence for association between these clusters and gliomas. Despite the broad similarity in the miRNA expression profiles, 15 miRNAs showed disparate expression between SC and gliomas. Ten miRNAs belong to the 2 SC-specific clusters and the remaining (mir135b, mir141, mir205, mir200C, and mir301a) have been previously shown to associate with malignancies. Our finding showed that all gliomas displayed NPC-like miRNA signatures, which may have implications for studies of glioma origins. Furthermore, careful study of the 15 miRNAs that differ in expression between SCs and gliomas, particularly those 5 that are not SC-specific, may enhance our understanding of gliomagenesis.

Verified
Journal Article
Open access
PDF file
Aliaksandr SkrahinAliaksandr Skrahin
Aliaksandr Skrahin
MHMia Horowitz
Mia Horowitz
MIMajdolen Istaiti
Majdolen Istaiti
VSVolha Skrahina
Volha Skrahina
JLJan Lukas
Jan Lukas
Ari ZimranAri Zimran
Ari Zimran
GBA1-associated Parkinson’s disease (GBA1-PD) is increasingly recognized as a distinct entity within the spectrum of parkinsonian disorders. This review explores the unique pathophysiological features, clinical progression, and genetic underpinnings that differentiate GBA1-PD from idiopathic Parkinson’s disease (iPD). GBA1-PD typically presents with earlier onset and more rapid progression, with a poor response to standard PD medications. It is marked by pronounced cognitive impairment and a higher burden of non-motor symptoms compared to iPD. Additionally, patients with GBA1-PD often exhibit a broader distribution of Lewy bodies within the brain, accentuating neurodegenerative processes. The pathogenesis of GBA1-PD is closely associated with mutations in the GBA1 gene, which encodes the lysosomal enzyme beta-glucocerebrosidase (GCase). In this review, we discuss two mechanisms by which GBA1 mutations contribute to disease development: ‘haploinsufficiency,’ where a single functional gene copy fails to produce a sufficient amount of GCase, and ‘gain of function,’ where the mutated GCase acquires harmful properties that directly impact cellular mechanisms for alpha-synuclein degradation, leading to alpha-synuclein aggregation and neuronal cell damage. Continued research is advancing our understanding of how these mechanisms contribute to the development and progression of GBA1-PD, with the ‘gain of function’ mechanism appearing to be the most plausible. This review also explores the implications of GBA1 mutations for therapeutic strategies, highlighting the need for early diagnosis and targeted interventions. Currently, small molecular chaperones have shown the most promising clinical results compared to other agents. This synthesis of clinical, pathological, and molecular aspects underscores the assertion that GBA1-PD is a distinct clinical and pathobiological PD phenotype, necessitating specific management and research approaches to better understand and treat this debilitating condition.

2 November 2009 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
MCMikhal E. Cohen
Mikhal E. Cohen
NMNaser Muja
Naser Muja
NFNina Fainstein
Nina Fainstein
JBJeff W.M. Bulte
Jeff W.M. Bulte
Tamir Ben-HurTamir Ben-Hur
Tamir Ben-Hur

21 September 2012 in Glia
Verified
Journal Article
Closed access
PDF file
NFNina Fainstein
Nina Fainstein
OEOfira Einstein
Ofira Einstein
MCMikhal E. Cohen
Mikhal E. Cohen
LBLivnat Brill
Livnat Brill
ILIris Lavon
Iris Lavon
Tamir Ben-HurTamir Ben-Hur
Tamir Ben-Hur

8 February 2011 in Magnetic Resonance in Medicine
Verified
Journal Article
Open access
PDF file
NMNaser Muja
Naser Muja
MCMikhal E. Cohen
Mikhal E. Cohen
JZJiangyang Zhang
Jiangyang Zhang
HKHeechul Kim
Heechul Kim
AGAssaf A. Gilad
Assaf A. Gilad
JBJeff W.M. Bulte
Jeff W.M. Bulte
As the complex pathogenesis of multiple sclerosis contributes to spatiotemporal variations in the trophic micromilieu of the central nervous system, the optimal intervention period for cell‐replacement therapy must be systematically defined. We applied serial, 3D high‐resolution magnetic resonance imaging to transplanted neural precursor cells (NPCs) labeled with superparamagnetic iron oxide nanoparticles and 5‐bromo‐2‐deoxyuridine, and compared the migration pattern of NPCs in acute inflamed (n = 10) versus chronic demyelinated (n = 9) brains of mice induced with experimental allergic encephalomyelitis (EAE). Serial in vivo and ex‐vivo 3D magnetic resonance imaging revealed that NPCs migrated 2.5 ± 1.3 mm along the corpus callosum in acute EAE. In chronic EAE, cell migration was slightly reduced (2.3 ± 1.3 mm) and only occurred in the lateral side of transplantation. Surprisingly, in 6/10 acute EAE brains, NPCs were found to migrate in a radial pattern along RECA‐1+ cortical blood vessels, in a pattern hitherto only reported for migrating glioblastoma cells. This striking radial biodistribution pattern was not detected in either chronic EAE or disease‐free control brains. In both acute and chronic EAE brain, Iba1+ microglia/macrophage number was significantly higher in central nervous system regions containing migrating NPCs. The existence of differential NPC migration patterns is an important consideration for implementing future translational studies in multiple sclerosis patients with variable disease. Magn Reson Med, 2011.

1 January 2013 in Neurobiology of Disease
Verified
Journal Article
Closed access
NFNina Fainstein
Nina Fainstein
MCMikhal E. Cohen
Mikhal E. Cohen
Tamir Ben-HurTamir Ben-Hur
Tamir Ben-Hur